Origanum majorana L. extract effects on kidney tissue in STZ-induced DM rats

Alican Cakar; Oguzhan Aydemir; Hümeysa Kiyak-kirmaci; Elif Beyzanur Polat; Turgut Taşkın; Levent Kabasakal; Hatice Kubra Elcioglu

Origanum majorana L. extract effects on kidney tissue in STZ-induced DM rats

Abstract

Diabetes mellitus is a chronic disease characterized by decreased insulin synthesis or increased blood glucose due to insulin resistance. In this study, we aimed to investigate the protective role of Origanum majorana L. on the biochemical parameters of rats induced by streptozotocin (STZ). Male Sprague-Dawley (SD) rats weighing 300-400 g were used. Rats were divided into 3 groups control, diabetes mellitus, and diabetes mellitus + Origanum majorana L. Citrate buffer was used i.p. in the control group. To induce experimental diabetes in rats, streptozotocin (60 mg/kg) was injected intraperitoneally (i.p.). After 48 hours, rats with blood glucose values higher than 200 mg/dL were considered diabetic. Diabetic rats were divided into two groups. While the first group was not treated, the second group received 200 mg/kg of Origanum majorana L. extract for 6 weeks. In this study, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and creatinine values were measured in serum. Malondialdehyde (MDA) and glutathione (GSH) levels were measured in kidney and liver tissues. It was found that AST, ALT, and creatinine values increased in diabetes and decreased significantly in the treatment group. MDA levels were increased and GSH values were decreased in diabetes. Origanum majorana L. treatment decreased lipid peroxidation and resulted in a significant increase in GSH levels. In conclusion, our findings show that Origanum majorana L. treatment has a protective effect against nephropathy in diabetes by preventing oxidative damage.

Keywords

References

[1] Wändell PE. Quality of life of patients with diabetes mellitus. An overview of research in primary health care in the Nordic countries. Scand J Prim Health Care. 2005; 23:68-74. https://doi.org/10.1080/02813430510015296.
[2] Zhao T, Sun S, Zhang H, Huang X, Yan M, Dong X, Wen Y, Wang H, Lan HY, Li P. Therapeutic Effects of Tangshen Formula on Diabetic Nephropathy in Rats. PLoS One. 2016; 25:11(1):0147693. https://doi.org/10.1371/journal.pone.0147693.
[3] Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016; 4:537-47. https://doi.org/10.1016/S2213-8587(16)30010-9.
[4] Ogurtsova K, Guariguata L, Barengo NC, Ruiz PL, Sacre JW, Karuranga S, Sun H, Boyko EJ, Magliano DJ. IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res Clin Pract. 2022; 183:109118. https://doi.org/10.1016/j.diabres.2021.109118.
[5] Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 2022; 18:525-39. https://doi.org/10.1038/s41574-022-00690-7.
[6] Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86. https://doi.org/10.1056/NEJM199309303291401.
[7] Bhatti JS, Sehrawat A, Mishra J, Sidhu IS, Navik U, Khullar N, Kumar S, Bhatti GK, Reddy PH. Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives. Free Radic Biol Med. 2022; 184:114-34. https://doi.org/10.1016/j.freeradbiomed.2022.03.019.
[8] Bouyahya A, Chamkhi I, Benali T, Guaouguaou FE, Balahbib A, Omari NE, Taha D, Belmehdi O, Ghokhan Z, Menyiy NE. Traditional use, phytochemistry, toxicology, and pharmacology of Origanum majorana L. J Ethnopharmacol. 2021; 265:113318. https://doi.org/10.1016/j.jep.2020.113318.

[9] Soliman MM, Nassan MA, Ismail TA. Origanum Majoranum Extract Modulates Gene Expression, Hepatic and Renal Changes in a Rat Model of Type 2 Diabetes. 2016; 15:45-54. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242351.
[10] Farag DBE, Yousry C, Al-Mahallawi AM, El-Askary HI, Meselhy MR, AbuBakr N. The efficacy of Origanum majorana nanocubosomal systems in ameliorating submandibular salivary gland alterations in streptozotocin-induced diabetic rats. Drug Deliv. 2022; 29:62-74. https://doi.org/10.1080/10717544.2021.2018522.
[11] Jozi F, Kheiripour N, Taheri MA, Ardjmand A, Ghavipanjeh G, Nasehi Z, Shahaboddin ME. L-Lysine Ameliorates Diabetic Nephropathy in Rats with Streptozotocin-Induced Diabetes Mellitus. Biomed Res Int. 2022; 4547312. https://doi.org/10.1155/2022/4547312.
[12] Mohammed ME, Abbas AM, Badi RM, Bashir SO, Osman OM, Morsy MD, Saeed AM. Effect of Acacia senegal on TGF-β1 and vascular mediators in a rat model of diabetic nephropathy. Arch Physiol Biochem. 2022; 128:1548-58. https://doi.org/10.1080/13813455.2020.1781901.
[13] Abdelmageed ME, Shehatou GS, Abdelsalam RA, Suddek GM, Salem HA. Cinnamaldehyde ameliorates STZ-induced rat diabetes through modulation of IRS1/PI3K/AKT2 pathway and AGEs/RAGE interaction. Naunyn Schmiedebergs Arch Pharmacol. 2019; 392:243-58. https://doi.org/10.1007/s00210-018-1583-4.
[14] Arigela CS, Nelli G, Gan SH, Sirajudeen KNS, Krishnan K, Rahman NA, Pasupuleti VR. Bitter Gourd Honey Ameliorates Hepatic and Renal Diabetic Complications on Type 2 Diabetes Rat Models by Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Mechanisms. Foods. 2021; 10(11):2872. https://doi.org/10.3390/foods10112872.
[15] Chahra C, Anis H, Bissene D, Mejda S, Jihène M, Salma N, Manel N, Sana BA, Hedi K, Maha BF. The effect of Origanum majorana tea on motor and non-motor symptoms in patients with idiopathic Parkinson's disease: A randomized controlled pilot study. Parkinsonism Relat Disord. 2021; 91:23-27. https://doi.org/10.1016/j.parkreldis.2021.08.013.
[16] Soliman AM, Desouky S, Marzouk M, Sayed AA. 2016. Origanum majorana Attenuates Nephrotoxicity of Cisplatin Anticancer Drug through Ameliorating Oxidative Stress. Nutrients. 2016; 8(5):264. https://doi.org/10.3390/nu8050264.
[17] Malik S, Suchal K, Khan SI, Bhatia J, Kishore K, Dinda AK, Arya DS. Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways. Am J Physiol Renal Physiol. 2017; 313:414-22. https://doi.org/10.1152/ajprenal.00393.2016.
[18] Ghosian Moghaddam M, Ansari I, Roghani M, Moradi M. The Effects of Origanum Majorana on Oxidative Stress and Histopathology of Renal Tissue among Streptozotocin-Induced Diabetic Rats. Thrita. 2013; 2:29-34. https://doi.org/10.5812/thrita.9282.
[19] Hussein Z, Yasir SM. Orıganum Majorana Attenuates Cıprofloxacın-Induced Nephropathy In Rats. Wiad Lek. 2022; 75:3046-9. https://doi.org/10.36740/WLek202212126.
[20] Refaie AA, Ramadan A, Mossa AT. Oxidative damage and nephrotoxicity induced by prallethrin in rat and the protective effect of Origanum majorana essential oil. Asian Pac J Trop Med. 2014; 7(1):506-13. https://doi.org/10.1016/S1995-7645(14)60282-0.

Details

Primary Language

English

Subjects

Medical Pharmacology

Journal Section

Research Article

Authors

Alican Cakar This is me
0009-0003-0965-2021
Türkiye

Oguzhan Aydemir This is me
0000-0002-1611-0947
Türkiye

Hümeysa Kiyak-kirmaci This is me
0000-0003-2574-4762
Türkiye

Elif Beyzanur Polat
0000-0002-3093-3595
Türkiye

Turgut Taşkın
0000-0001-8475-6478
Türkiye

Levent Kabasakal
0000-0002-5474-6436
Türkiye

Hatice Kubra Elcioglu ^* This is me
0000-0002-3312-3029
Türkiye

Publication Date

June 28, 2025

Submission Date

May 2, 2023

Acceptance Date

July 10, 2023

Published in Issue

Year 2023 Volume: 27 Number: 4

IZ

https://izlik.org/JA83LH27WR

Cite

RIS / Bibtex

APA

Cakar, A., Aydemir, O., Kiyak-kirmaci, H., Polat, E. B., Taşkın, T., Kabasakal, L., & Elcioglu, H. K. (2025). Origanum majorana L. extract effects on kidney tissue in STZ-induced DM rats. Journal of Research in Pharmacy, 27(4), 1638-1644. https://izlik.org/JA83LH27WR

AMA

1.Cakar A, Aydemir O, Kiyak-kirmaci H, et al. Origanum majorana L. extract effects on kidney tissue in STZ-induced DM rats. J. Res. Pharm. 2025;27(4):1638-1644. https://izlik.org/JA83LH27WR

Chicago

Cakar, Alican, Oguzhan Aydemir, Hümeysa Kiyak-kirmaci, et al. 2025. “Origanum Majorana L. Extract Effects on Kidney Tissue in STZ-Induced DM Rats”. Journal of Research in Pharmacy 27 (4): 1638-44. https://izlik.org/JA83LH27WR.

EndNote

Cakar A, Aydemir O, Kiyak-kirmaci H, Polat EB, Taşkın T, Kabasakal L, Elcioglu HK (July 1, 2025) Origanum majorana L. extract effects on kidney tissue in STZ-induced DM rats. Journal of Research in Pharmacy 27 4 1638–1644.

IEEE

[1]A. Cakar et al., “Origanum majorana L. extract effects on kidney tissue in STZ-induced DM rats”, J. Res. Pharm., vol. 27, no. 4, pp. 1638–1644, July 2025, [Online]. Available: https://izlik.org/JA83LH27WR

ISNAD

Cakar, Alican - Aydemir, Oguzhan - Kiyak-kirmaci, Hümeysa - Polat, Elif Beyzanur - Taşkın, Turgut - Kabasakal, Levent - Elcioglu, Hatice Kubra. “Origanum Majorana L. Extract Effects on Kidney Tissue in STZ-Induced DM Rats”. Journal of Research in Pharmacy 27/4 (July 1, 2025): 1638-1644. https://izlik.org/JA83LH27WR.

JAMA

1.Cakar A, Aydemir O, Kiyak-kirmaci H, Polat EB, Taşkın T, Kabasakal L, Elcioglu HK. Origanum majorana L. extract effects on kidney tissue in STZ-induced DM rats. J. Res. Pharm. 2025;27:1638–1644.

MLA

Cakar, Alican, et al. “Origanum Majorana L. Extract Effects on Kidney Tissue in STZ-Induced DM Rats”. Journal of Research in Pharmacy, vol. 27, no. 4, July 2025, pp. 1638-44, https://izlik.org/JA83LH27WR.

Vancouver

1.Alican Cakar, Oguzhan Aydemir, Hümeysa Kiyak-kirmaci, Elif Beyzanur Polat, Turgut Taşkın, Levent Kabasakal, Hatice Kubra Elcioglu. Origanum majorana L. extract effects on kidney tissue in STZ-induced DM rats. J. Res. Pharm. [Internet]. 2025 Jul. 1;27(4):1638-44. Available from: https://izlik.org/JA83LH27WR